Savella, which is approved for the management of fibromyalgia, posted sales of $24.6 million, up significantly from the year-earlier sales of $15.4 million. Sales are being driven by the company's promotional efforts.
Savella was launched in late April 2009. We believe the product may have multi-hundred million dollar potential. In early October 2010, Savella was moved into tier II unrestricted coverage on several managed care organizations. Improved formulary access should help boost sales. Forest Labs entered into a collaboration and distribution agreement with Janssen to commercialize Bystolic and Savella in Canada.
http://www.prnewswire.com/news-releases/zacks-analyst-blog-highlights-comerica-incorporated-sterling-bancshares-citigroup-forest-laboratories-and-ironwood-pharmaceuticals-114201369.html
Savella was launched in late April 2009. We believe the product may have multi-hundred million dollar potential. In early October 2010, Savella was moved into tier II unrestricted coverage on several managed care organizations. Improved formulary access should help boost sales. Forest Labs entered into a collaboration and distribution agreement with Janssen to commercialize Bystolic and Savella in Canada.
http://www.prnewswire.com/news-releases/zacks-analyst-blog-highlights-comerica-incorporated-sterling-bancshares-citigroup-forest-laboratories-and-ironwood-pharmaceuticals-114201369.html
No comments:
Post a Comment